1 |
SIGMAR1
| 2件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases | D00848
D00848
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
2 |
SIGMAR1
| 2件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
3 |
SIGMAR1
| 2件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases | D03744
D03744
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
4 |
CYSLTR1
| 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction | D00529
D00529
|
Montelukast
| 8件: 6 6, 13, 46, 61, 63, 85, 98, 228 |
5 |
CYSLTR1
| 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction | D08229
D08229
|
Montelukast
| 8件: 6 6, 13, 46, 61, 63, 85, 98, 228 |
6 |
HRH3
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D09870
D09870
|
Bavisant
| 1件: 6 6 |
7 |
HRH3
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10749
D10749
|
Pitolisant
| 3件: 6 6, 113, 193 |
8 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00397
D00397
|
Tropicamide
| 3件: 6 6, 13, 19 |
9 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
10 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00722
D00722
|
Oxybutynin
| 3件: 6 6, 13, 53 |
11 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
12 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D02212
D02212
|
Ipratropium
| 2件: 6 6, 86 |
13 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
14 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D00397
D00397
|
Tropicamide
| 3件: 6 6, 13, 19 |
15 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
16 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D00525
D00525
|
Pilocarpine
| 3件: 6 6, 53, 299 |
17 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D00722
D00722
|
Oxybutynin
| 3件: 6 6, 13, 53 |
18 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
19 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D02200
D02200
|
Pilocarpine
| 3件: 6 6, 53, 299 |
20 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D02212
D02212
|
Ipratropium
| 2件: 6 6, 86 |
21 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D05478
D05478
|
Pilocarpine
| 3件: 6 6, 53, 299 |
22 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D07226
D07226
|
Fesoterodine
| 1件: 6 6 |
23 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
24 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00397
D00397
|
Tropicamide
| 3件: 6 6, 13, 19 |
25 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
26 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00525
D00525
|
Pilocarpine
| 3件: 6 6, 53, 299 |
27 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00722
D00722
|
Oxybutynin
| 3件: 6 6, 13, 53 |
28 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
29 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D01269
D01269
|
Solifenacin
| 3件: 6 6, 13, 53 |
30 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D01699
D01699
|
Darifenacin
| 2件: 6 6, 13 |
31 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D02200
D02200
|
Pilocarpine
| 3件: 6 6, 53, 299 |
32 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D02212
D02212
|
Ipratropium
| 2件: 6 6, 86 |
33 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D03654
D03654
|
Darifenacin
| 2件: 6 6, 13 |
34 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D05478
D05478
|
Pilocarpine
| 3件: 6 6, 53, 299 |
35 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D07226
D07226
|
Fesoterodine
| 1件: 6 6 |
36 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D08522
D08522
|
Solifenacin
| 3件: 6 6, 13, 53 |
37 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
38 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D00397
D00397
|
Tropicamide
| 3件: 6 6, 13, 19 |
39 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
40 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D00722
D00722
|
Oxybutynin
| 3件: 6 6, 13, 53 |
41 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
42 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D02212
D02212
|
Ipratropium
| 2件: 6 6, 86 |
43 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
44 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00397
D00397
|
Tropicamide
| 3件: 6 6, 13, 19 |
45 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00465
D00465
|
Oxybutynin
| 3件: 6 6, 13, 53 |
46 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00722
D00722
|
Oxybutynin
| 3件: 6 6, 13, 53 |
47 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
48 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D02212
D02212
|
Ipratropium
| 2件: 6 6, 86 |
49 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
50 |
CHRNA1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
51 |
CHRNA1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
52 |
CHRNA1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
53 |
CHRNA2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
54 |
CHRNA2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
55 |
CHRNA2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
56 |
CHRNA3
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
57 |
CHRNA3
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
58 |
CHRNA3
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
59 |
CHRNA4
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
60 |
CHRNA4
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
61 |
CHRNA4
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
62 |
CHRNA4
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D08669
D08669
|
Varenicline
| 2件: 6 6, 18 |
63 |
CHRNA5
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
64 |
CHRNA5
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
65 |
CHRNA5
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
66 |
CHRNA7
| 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
67 |
CHRNA7
| 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
68 |
CHRNA7
| 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
69 |
CHRNB1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
70 |
CHRNB1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
71 |
CHRNB1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
72 |
CHRNB2
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
73 |
CHRNB2
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
74 |
CHRNB2
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
75 |
CHRNB2
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D08669
D08669
|
Varenicline
| 2件: 6 6, 18 |
76 |
CHRNB3
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
77 |
CHRNB3
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
78 |
CHRNB3
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
79 |
CHRNB4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
80 |
CHRNB4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
81 |
CHRNB4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
82 |
CHRND
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
83 |
CHRND
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
84 |
CHRND
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
85 |
CHRNE
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
86 |
CHRNE
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
87 |
CHRNE
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
88 |
CHRNG
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
89 |
CHRNG
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
90 |
CHRNG
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
91 |
CLCN2
| 1件: Mineral absorption Mineral absorption | D04790
D04790
|
Lubiprostone
| 4件: 6 6, 13, 290, 299 |
92 |
CNR1
| 4件: Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D05099
D05099
|
Nabilone
| 2件: 6 6, 13 |
93 |
CNR1
| 4件: Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D10915
D10915
|
Cannabidiol
| 19件: 2 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
94 |
CNR2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05099
D05099
|
Nabilone
| 2件: 6 6, 13 |
95 |
CNR2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10915
D10915
|
Cannabidiol
| 18件: 6 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
96 |
COMT
| 4件: Steroid hormone biosynthesis Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse | D00781
D00781
|
Entacapone
| 2件: 6 6, 17 |
97 |
COMT
| 4件: Steroid hormone biosynthesis Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse | D00786
D00786
|
Tolcapone
| 3件: 6 6, 28, 127 |
98 |
COMT
| 4件: Steroid hormone biosynthesis Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse | D10825
D10825
|
Opicapone
| 1件: 6 6 |
99 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
100 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
101 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
102 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
103 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D04641
D04641
|
Istradefylline
| 1件: 6 6 |
104 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D09717
D09717
|
Preladenant
| 1件: 6 6 |
105 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D10174
D10174
|
Tozadenant
| 1件: 6 6 |
106 |
CSF2RA
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D05803
D05803
|
Sargramostim
| 7件: 6 6, 28, 60, 62, 96, 229, 285 |
107 |
CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03235
D03235
|
Filgrastim
| 34件: 2 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
108 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
109 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00610
D00610
|
Terazosin
| 1件: 6 6 |
110 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
111 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01307
D01307
|
Midodrine
| 3件: 6 6, 17, 58 |
112 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
113 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
114 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
115 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
116 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
117 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
118 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00610
D00610
|
Terazosin
| 1件: 6 6 |
119 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
120 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01307
D01307
|
Midodrine
| 3件: 6 6, 17, 58 |
121 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
122 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
123 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
124 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
125 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
126 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
127 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00610
D00610
|
Terazosin
| 1件: 6 6 |
128 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
129 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01307
D01307
|
Midodrine
| 3件: 6 6, 17, 58 |
130 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01965
D01965
|
Silodosin
| 2件: 6 6, 13 |
131 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
132 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
133 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
134 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
135 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
136 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
137 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
138 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
139 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00604
D00604
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
140 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
141 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
142 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
143 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
144 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
145 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
146 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
147 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
148 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00604
D00604
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
149 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
150 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
151 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
152 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
153 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
154 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
155 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
156 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
157 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00604
D00604
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
158 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
159 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
160 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
161 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
162 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
163 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
164 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00432
D00432
|
Nadolol
| 1件: 6 6 |
165 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00483
D00483
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
166 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
167 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
168 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
169 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08443
D08443
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
170 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
171 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00432
D00432
|
Nadolol
| 1件: 6 6 |
172 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00483
D00483
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
173 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
174 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02151
D02151
|
Tulobuterol
| 1件: 6 6 |
175 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
176 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
177 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D07713
D07713
|
Clenbuterol
| 5件: 1 1, 2, 6, 13, 256 |
178 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
179 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00483
D00483
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
180 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
181 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
182 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
183 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D09535
D09535
|
Mirabegron
| 4件: 6 6, 13, 53, 226 |
184 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00251
D00251
|
Captopril
| 8件: 6 6, 17, 46, 86, 96, 97, 107, 271 |
185 |
DDC
| 9件: Tyrosine metabolism Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism | D00558
D00558
|
Carbidopa
| 9件: 2 2, 4, 6, 13, 17, 90, 140, 164, 201 |
186 |
DDC
| 9件: Tyrosine metabolism Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism | D03082
D03082
|
Benserazide
| 1件: 6 6 |
187 |
HTR3C
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
188 |
HTR3C
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
189 |
HTR3C
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00678
D00678
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
190 |
HTR3C
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D10184
D10184
|
Vortioxetine
| 1件: 6 6 |
191 |
NQO1
| 7件: Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D00564
D00564
|
Warfarin
| 13件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
192 |
NQO1
| 7件: Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D01280
D01280
|
Warfarin
| 13件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
193 |
NQO1
| 7件: Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D08682
D08682
|
Warfarin
| 13件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
194 |
DPP4
| 1件: Protein digestion and absorption Protein digestion and absorption | D08516
D08516
|
Sitagliptin
| 4件: 6 6, 75, 233, 299 |
195 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D00059
D00059
|
Levodopa
| 8件: 2 2, 4, 6, 17, 90, 140, 164, 201 |
196 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D00502
D00502
|
Pergolide
| 1件: 6 6 |
197 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D00633
D00633
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
198 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D02004
D02004
|
Apomorphine
| 3件: 5 5, 6, 7 |
199 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D07460
D07460
|
Apomorphine
| 3件: 5 5, 6, 7 |
200 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D07870
D07870
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
201 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D08339
D08339
|
Pergolide
| 1件: 6 6 |
202 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D11431
D11431
|
Tavapadon
| 1件: 6 6 |
203 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D11839
D11839
|
Foslevodopa
| 1件: 6 6 |
204 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00059
D00059
|
Levodopa
| 8件: 2 2, 4, 6, 17, 90, 140, 164, 201 |
205 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00458
D00458
|
Quetiapine
| 2件: 6 6, 13 |
206 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00502
D00502
|
Pergolide
| 1件: 6 6 |
207 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00559
D00559
|
Pramipexole
| 3件: 2 2, 6, 20 |
208 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00633
D00633
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
209 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00702
D00702
|
Buspirone
| 3件: 6 6, 51, 179 |
210 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00780
D00780
|
Bromocriptine
| 2件: 6 6, 74 |
211 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00784
D00784
|
Ropinirole
| 4件: 2 2, 6, 74, 309 |
212 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00987
D00987
|
Cabergoline
| 3件: 6 6, 74, 75 |
213 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D01164
D01164
|
Aripiprazole
| 2件: 6 6, 206 |
214 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D01226
D01226
|
Sulpiride
| 5件: 2 2, 6, 17, 46, 70 |
215 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D01462
D01462
|
Lisuride
| 2件: 6 6, 86 |
216 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D01745
D01745
|
Domperidone
| 5件: 6 6, 13, 17, 51, 230 |
217 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D02004
D02004
|
Apomorphine
| 3件: 5 5, 6, 7 |
218 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D03165
D03165
|
Bromocriptine
| 2件: 6 6, 74 |
219 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D05575
D05575
|
Pramipexole
| 3件: 2 2, 6, 20 |
220 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D05768
D05768
|
Rotigotine
| 2件: 6 6, 127 |
221 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07305
D07305
|
Piribedil
| 1件: 6 6 |
222 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07309
D07309
|
Melperone
| 1件: 6 6 |
223 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07460
D07460
|
Apomorphine
| 3件: 5 5, 6, 7 |
224 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07593
D07593
|
Buspirone
| 3件: 6 6, 51, 179 |
225 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07868
D07868
|
Domperidone
| 5件: 6 6, 13, 17, 51, 230 |
226 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07870
D07870
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
227 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D08132
D08132
|
Lisuride
| 2件: 6 6, 86 |
228 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D08339
D08339
|
Pergolide
| 1件: 6 6 |
229 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D08456
D08456
|
Quetiapine
| 2件: 6 6, 13 |
230 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D08489
D08489
|
Ropinirole
| 4件: 2 2, 6, 74, 309 |
231 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D08549
D08549
|
Sulpiride
| 5件: 2 2, 6, 17, 46, 70 |
232 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D09397
D09397
|
Pardoprunox
| 1件: 6 6 |
233 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D09953
D09953
|
Pridopidine
| 3件: 2 2, 6, 8 |
234 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D11839
D11839
|
Foslevodopa
| 1件: 6 6 |
235 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00059
D00059
|
Levodopa
| 8件: 2 2, 4, 6, 17, 90, 140, 164, 201 |
236 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00559
D00559
|
Pramipexole
| 3件: 2 2, 6, 20 |
237 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00633
D00633
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
238 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00784
D00784
|
Ropinirole
| 4件: 2 2, 6, 74, 309 |
239 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D01164
D01164
|
Aripiprazole
| 2件: 6 6, 206 |
240 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D01462
D01462
|
Lisuride
| 2件: 6 6, 86 |
241 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D05575
D05575
|
Pramipexole
| 3件: 2 2, 6, 20 |
242 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D07305
D07305
|
Piribedil
| 1件: 6 6 |
243 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D07870
D07870
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
244 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D08132
D08132
|
Lisuride
| 2件: 6 6, 86 |
245 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D08489
D08489
|
Ropinirole
| 4件: 2 2, 6, 74, 309 |
246 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D09397
D09397
|
Pardoprunox
| 1件: 6 6 |
247 |
DRD3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D11839
D11839
|
Foslevodopa
| 1件: 6 6 |
248 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00059
D00059
|
Levodopa
| 8件: 2 2, 4, 6, 17, 90, 140, 164, 201 |
249 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00283
D00283
|
Clozapine
| 1件: 6 6 |
250 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00559
D00559
|
Pramipexole
| 3件: 2 2, 6, 20 |
251 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00633
D00633
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
252 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00784
D00784
|
Ropinirole
| 4件: 2 2, 6, 74, 309 |
253 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D01462
D01462
|
Lisuride
| 2件: 6 6, 86 |
254 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D05575
D05575
|
Pramipexole
| 3件: 2 2, 6, 20 |
255 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D07870
D07870
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
256 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D08132
D08132
|
Lisuride
| 2件: 6 6, 86 |
257 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D08489
D08489
|
Ropinirole
| 4件: 2 2, 6, 74, 309 |
258 |
DRD4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D11839
D11839
|
Foslevodopa
| 1件: 6 6 |
259 |
DRD5
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00059
D00059
|
Levodopa
| 8件: 2 2, 4, 6, 17, 90, 140, 164, 201 |
260 |
DRD5
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00633
D00633
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
261 |
DRD5
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse | D07870
D07870
|
Dopamine
| 4件: 6 6, 7, 74, 299 |
262 |
DRD5
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse | D11431
D11431
|
Tavapadon
| 1件: 6 6 |
263 |
DRD5
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse | D11839
D11839
|
Foslevodopa
| 1件: 6 6 |
264 |
ABAT
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
265 |
HTR3D
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
266 |
HTR3D
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
267 |
HTR3D
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00678
D00678
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
268 |
HTR3D
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D10184
D10184
|
Vortioxetine
| 1件: 6 6 |
269 |
EPOR
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03231
D03231
|
Erythropoietin
| 10件: 2 2, 6, 13, 18, 22, 46, 47, 70, 95, 96 |
270 |
F8
| 1件: Complement and coagulation cascades Complement and coagulation cascades | D00291
D00291
|
Desmopressin
| 6件: 6 6, 64, 72, 75, 225, 288 |
271 |
F8
| 1件: Complement and coagulation cascades Complement and coagulation cascades | D02235
D02235
|
Desmopressin
| 6件: 6 6, 64, 72, 75, 225, 288 |
272 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D01968
D01968
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
273 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D06378
D06378
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
274 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D06379
D06379
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
275 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D08689
D08689
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
276 |
MTOR
| 51件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D00753
D00753
|
Sirolimus
| 41件: 2 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
277 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
278 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
279 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00548
D00548
|
Etomidate
| 1件: 6 6 |
280 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
281 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
282 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
283 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
284 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
285 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
286 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
287 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
288 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
289 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
290 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
291 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
292 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
293 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
294 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
295 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
296 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
297 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
298 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
299 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
300 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
301 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
302 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
303 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
304 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
305 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
306 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
307 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
308 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
309 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
310 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
311 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
312 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
313 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
314 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
315 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
316 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
317 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
318 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
319 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
320 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
321 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
322 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
323 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
324 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
325 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
326 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
327 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
328 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
329 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
330 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
331 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
332 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
333 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
334 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
335 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
336 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
337 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
338 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
339 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
340 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
341 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
342 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
343 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
344 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
345 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
346 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
347 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
348 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
349 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
350 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
351 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
352 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
353 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
354 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
355 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
356 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
357 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
358 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
359 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
360 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
361 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
362 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
363 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
364 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
365 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
366 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
367 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
368 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
369 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
370 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
371 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
372 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
373 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
374 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
375 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
376 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
377 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
378 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
379 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
380 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
381 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
382 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
383 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
384 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
385 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
386 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
387 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
388 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
389 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
390 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
391 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
392 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
393 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
394 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
395 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
396 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
397 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
398 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
399 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
400 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
401 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
402 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
403 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
404 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
405 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
406 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
407 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
408 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
409 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
410 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
411 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
412 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
413 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
414 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
415 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
416 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
417 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
418 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
419 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
420 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
421 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
422 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
423 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
424 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
425 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
426 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
427 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
428 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
429 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
430 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
431 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
432 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
433 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
434 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
435 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
436 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
437 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
438 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
439 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
440 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
441 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
442 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
443 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
444 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
445 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
446 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
447 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
448 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
449 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
450 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
451 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
452 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
453 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
454 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
455 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
456 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
457 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
458 |
GAD1
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
459 |
GAD2
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
460 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D08953
D08953
|
Nilotinib
| 5件: 6 6, 8, 34, 51, 86 |
461 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D09664
D09664
|
Saracatinib
| 3件: 6 6, 89, 272 |
462 |
GLP1R
| 3件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion | D04121
D04121
|
Exenatide
| 6件: 6 6, 17, 72, 78, 193, 233 |
463 |
GLP1R
| 3件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion | D06404
D06404
|
Liraglutide
| 3件: 6 6, 75, 193 |
464 |
GLP1R
| 3件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion | D09729
D09729
|
Lixisenatide
| 1件: 6 6 |
465 |
GLP1R
| 3件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion | D10025
D10025
|
Semaglutide
| 1件: 6 6 |
466 |
HTR3E
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
467 |
HTR3E
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
468 |
HTR3E
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00678
D00678
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
469 |
HTR3E
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D10184
D10184
|
Vortioxetine
| 1件: 6 6 |
470 |
GRIA1
| 14件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
471 |
GRIA1
| 14件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D02696
D02696
|
Talampanel
| 2件: 2 2, 6 |
472 |
GRIA1
| 14件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D08964
D08964
|
Perampanel
| 3件: 2 2, 6, 144 |
473 |
GRIA2
| 15件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
474 |
GRIA2
| 15件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D02696
D02696
|
Talampanel
| 2件: 2 2, 6 |
475 |
GRIA2
| 15件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D08964
D08964
|
Perampanel
| 3件: 2 2, 6, 144 |
476 |
GRIA3
| 13件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
477 |
GRIA3
| 13件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D02696
D02696
|
Talampanel
| 2件: 2 2, 6 |
478 |
GRIA3
| 13件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D08964
D08964
|
Perampanel
| 3件: 2 2, 6, 144 |
479 |
GRIA4
| 10件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
480 |
GRIA4
| 10件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D02696
D02696
|
Talampanel
| 2件: 2 2, 6 |
481 |
GRIA4
| 10件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D08964
D08964
|
Perampanel
| 3件: 2 2, 6, 144 |
482 |
GRIK1
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
483 |
GRIK2
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
484 |
GRIK3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
485 |
GRIK4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
486 |
GRIK5
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
487 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00711
D00711
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
488 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00777
D00777
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
489 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00848
D00848
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
490 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D02780
D02780
|
Acamprosate
| 2件: 6 6, 206 |
491 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
492 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03744
D03744
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
493 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D04905
D04905
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
494 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
495 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
496 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
497 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08174
D08174
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
498 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00711
D00711
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
499 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00777
D00777
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
500 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00848
D00848
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
501 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D02780
D02780
|
Acamprosate
| 2件: 6 6, 206 |
502 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
503 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03744
D03744
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
504 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D04905
D04905
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
505 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
506 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
507 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
508 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D08174
D08174
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
509 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00711
D00711
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
510 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00777
D00777
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
511 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00848
D00848
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
512 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D02780
D02780
|
Acamprosate
| 2件: 6 6, 206 |
513 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
514 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03744
D03744
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
515 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D04905
D04905
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
516 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
517 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
518 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
519 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D08174
D08174
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
520 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00711
D00711
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
521 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00777
D00777
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
522 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00848
D00848
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
523 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D02780
D02780
|
Acamprosate
| 2件: 6 6, 206 |
524 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
525 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03744
D03744
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
526 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D04905
D04905
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
527 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
528 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
529 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
530 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08174
D08174
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
531 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00711
D00711
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
532 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00777
D00777
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
533 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00848
D00848
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
534 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D02780
D02780
|
Acamprosate
| 2件: 6 6, 206 |
535 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
536 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03744
D03744
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
537 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D04905
D04905
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
538 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
539 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
540 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
541 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D08174
D08174
|
Memantine
| 7件: 2 2, 6, 8, 13, 49, 127, 205 |
542 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00088
D00088
|
Hydrocortisone
| 11件: 6 6, 41, 46, 53, 75, 78, 81, 83, 97, 98, 299 |
543 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407
D00407
|
Methylprednisolone
| 47件: 6 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
544 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00473
D00473
|
Prednisone
| 47件: 6 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
545 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00751
D00751
|
Methylprednisolone
| 47件: 6 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
546 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00976
D00976
|
Hydrocortisone cypionate
| 3件: 6 6, 81, 83 |
547 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00979
D00979
|
Methylprednisolone
| 47件: 6 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
548 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01442
D01442
|
Hydrocortisone succinate
| 3件: 6 6, 81, 83 |
549 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05000
D05000
|
Methylprednisolone
| 47件: 6 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
550 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05001
D05001
|
Methylprednisolone
| 47件: 6 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
551 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05002
D05002
|
Methylprednisolone
| 47件: 6 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
552 |
GUCY2C
| 2件: Purine metabolism Purine metabolism, Metabolic pathways | D09355
D09355
|
Linaclotide
| 2件: 6 6, 97 |
553 |
HCRTR1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10082
D10082
|
Suvorexant
| 2件: 6 6, 13 |
554 |
HCRTR2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10082
D10082
|
Suvorexant
| 2件: 6 6, 13 |
555 |
HMGCR
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D00359
D00359
|
Lovastatin
| 11件: 6 6, 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 |
556 |
HMGCR
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D00434
D00434
|
Simvastatin
| 21件: 6 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 |
557 |
HMGCR
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D01915
D01915
|
Rosuvastatin
| 11件: 6 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299 |
558 |
HMGCR
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D08492
D08492
|
Rosuvastatin
| 11件: 6 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299 |
559 |
HPD
| 5件: Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Tyrosine metabolism, Phenylalanine metabolism, Metabolic pathways, Biosynthesis of cofactors | D05177
D05177
|
Nitisinone
| 3件: 6 6, 164, 241 |
560 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00814
D00814
|
Doxepin
| 1件: 6 6 |
561 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D07875
D07875
|
Doxepin
| 1件: 6 6 |
562 |
HRH2
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion | D00318
D00318
|
Famotidine
| 7件: 6 6, 46, 61, 86, 98, 107, 300 |
563 |
HTR1A
| 4件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction | D00702
D00702
|
Buspirone
| 3件: 6 6, 51, 179 |
564 |
HTR1A
| 4件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction | D01164
D01164
|
Aripiprazole
| 2件: 6 6, 206 |
565 |
HTR1A
| 4件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction | D07593
D07593
|
Buspirone
| 3件: 6 6, 51, 179 |
566 |
HTR1A
| 4件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction | D09397
D09397
|
Pardoprunox
| 1件: 6 6 |
567 |
HTR1A
| 4件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction | D10184
D10184
|
Vortioxetine
| 1件: 6 6 |
568 |
HTR1B
| 4件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction | D00415
D00415
|
Zolmitriptan
| 1件: 6 6 |
569 |
HTR1D
| 4件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction | D00415
D00415
|
Zolmitriptan
| 1件: 6 6 |
570 |
HTR2A
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D00283
D00283
|
Clozapine
| 1件: 6 6 |
571 |
HTR2A
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D00458
D00458
|
Quetiapine
| 2件: 6 6, 13 |
572 |
HTR2A
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D01164
D01164
|
Aripiprazole
| 2件: 6 6, 206 |
573 |
HTR2A
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D08456
D08456
|
Quetiapine
| 2件: 6 6, 13 |
574 |
HTR2A
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D09645
D09645
|
Nelotanserin
| 1件: 6 6 |
575 |
HTR2C
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D00283
D00283
|
Clozapine
| 1件: 6 6 |
576 |
HTR2C
| 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D02578
D02578
|
Agomelatine
| 1件: 6 6 |
577 |
HTR3A
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
578 |
HTR3A
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
579 |
HTR3A
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00678
D00678
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
580 |
HTR3A
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D10184
D10184
|
Vortioxetine
| 1件: 6 6 |
581 |
KCNA4
| 2件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome | D04127
D04127
|
Dalfampridine
| 5件: 3 3, 4, 6, 13, 14 |
582 |
KCNC3
| 1件: Spinocerebellar ataxia Spinocerebellar ataxia | D04127
D04127
|
Dalfampridine
| 3件: 6 6, 13, 14 |
583 |
KCND2
| 1件: Serotonergic synapse Serotonergic synapse | D04127
D04127
|
Dalfampridine
| 3件: 6 6, 13, 14 |
584 |
KCND3
| 1件: Spinocerebellar ataxia Spinocerebellar ataxia | D04127
D04127
|
Dalfampridine
| 3件: 6 6, 13, 14 |
585 |
KCNJ11
| 3件: Insulin secretion Insulin secretion, GnRH secretion, Type II diabetes mellitus | D00594
D00594
|
Repaglinide
| 3件: 6 6, 21, 299 |
586 |
KIT
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D08953
D08953
|
Nilotinib
| 5件: 6 6, 8, 34, 51, 86 |
587 |
KIT
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D10229
D10229
|
Masitinib
| 6件: 2 2, 5, 6, 13, 46, 96 |
588 |
MAOA
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D00505
D00505
|
Phenelzine
| 1件: 6 6 |
589 |
MAOA
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D02561
D02561
|
Moclobemide
| 1件: 6 6 |
590 |
MAOA
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D02579
D02579
|
Iproniazid
| 1件: 6 6 |
591 |
MAOA
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D08349
D08349
|
Phenelzine
| 1件: 6 6 |
592 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D00505
D00505
|
Phenelzine
| 1件: 6 6 |
593 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D00785
D00785
|
Selegiline
| 1件: 6 6 |
594 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D02562
D02562
|
Rasagiline
| 7件: 2 2, 5, 6, 13, 17, 58, 66 |
595 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D02579
D02579
|
Iproniazid
| 1件: 6 6 |
596 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D03731
D03731
|
Selegiline
| 1件: 6 6 |
597 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D08349
D08349
|
Phenelzine
| 1件: 6 6 |
598 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D08469
D08469
|
Rasagiline
| 7件: 2 2, 5, 6, 13, 17, 58, 66 |
599 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D10158
D10158
|
Safinamide
| 2件: 6 6, 17 |
600 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D10829
D10829
|
Rasagiline
| 7件: 2 2, 5, 6, 13, 17, 58, 66 |
601 |
NR3C2
| 1件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption | D00986
D00986
|
Fludrocortisone
| 3件: 6 6, 17, 81 |
602 |
NR3C2
| 1件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption | D07967
D07967
|
Fludrocortisone
| 3件: 6 6, 17, 81 |
603 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D00487
D00487
|
Pyridostigmine
| 4件: 3 3, 6, 11, 256 |
604 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D00670
D00670
|
Donepezil
| 9件: 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
605 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D02173
D02173
|
Galantamine
| 2件: 6 6, 127 |
606 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D02558
D02558
|
Rivastigmine
| 3件: 5 5, 6, 13 |
607 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D03822
D03822
|
Rivastigmine
| 3件: 5 5, 6, 13 |
608 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D04292
D04292
|
Galantamine
| 2件: 6 6, 127 |
609 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D07869
D07869
|
Donepezil
| 9件: 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
610 |
MTNR1A
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D02578
D02578
|
Agomelatine
| 1件: 6 6 |
611 |
MTNR1A
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D02689
D02689
|
Ramelteon
| 3件: 6 6, 8, 46 |
612 |
MTNR1A
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D08170
D08170
|
Melatonin
| 12件: 6 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202 |
613 |
MTNR1B
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D02578
D02578
|
Agomelatine
| 1件: 6 6 |
614 |
MTNR1B
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D02689
D02689
|
Ramelteon
| 3件: 6 6, 8, 46 |
615 |
MTNR1B
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D08170
D08170
|
Melatonin
| 12件: 6 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202 |
616 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
617 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01207
D01207
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
618 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05259
D05259
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
619 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05261
D05261
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
620 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
621 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01207
D01207
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
622 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05259
D05259
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
623 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05261
D05261
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
624 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D01340
D01340
|
Naloxone
| 2件: 6 6, 226 |
625 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D02095
D02095
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
626 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D03783
D03783
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
627 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05111
D05111
|
Nalmefene
| 1件: 6 6 |
628 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
629 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05312
D05312
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
630 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05462
D05462
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
631 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08249
D08249
|
Naloxone
| 2件: 6 6, 226 |
632 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01340
D01340
|
Naloxone
| 2件: 6 6, 226 |
633 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02095
D02095
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
634 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03783
D03783
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
635 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05111
D05111
|
Nalmefene
| 1件: 6 6 |
636 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
637 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05312
D05312
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
638 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05462
D05462
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
639 |
OPRK1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D08249
D08249
|
Naloxone
| 2件: 6 6, 226 |
640 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D01177
D01177
|
Remifentanil
| 2件: 6 6, 70 |
641 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D01340
D01340
|
Naloxone
| 2件: 6 6, 226 |
642 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D02095
D02095
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
643 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D03783
D03783
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
644 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D05111
D05111
|
Nalmefene
| 1件: 6 6 |
645 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D05113
D05113
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
646 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D05312
D05312
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
647 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D05462
D05462
|
Oxycodone
| 7件: 6 6, 13, 46, 70, 226, 231, 298 |
648 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D08249
D08249
|
Naloxone
| 2件: 6 6, 226 |
649 |
OPRM1
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D08473
D08473
|
Remifentanil
| 2件: 6 6, 70 |
650 |
OXTR
| 4件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway | D00089
D00089
|
Oxytocin
| 6件: 6 6, 72, 127, 193, 206, 226 |
651 |
PDE2A
| 6件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
652 |
PDE2A
| 6件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
653 |
PDE3A
| 6件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
654 |
PDE3A
| 6件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
655 |
PDE3B
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
656 |
PDE3B
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
657 |
PDE4A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
658 |
PDE4A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
659 |
PDE4B
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
660 |
PDE4B
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
661 |
PDE4C
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
662 |
PDE4C
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
663 |
PDE4D
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
664 |
PDE4D
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
665 |
PDE1B
| 7件: Purine metabolism Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
666 |
PDE1B
| 7件: Purine metabolism Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
667 |
PDGFRA
| 20件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08953
D08953
|
Nilotinib
| 5件: 6 6, 8, 34, 51, 86 |
668 |
PDGFRB
| 19件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08953
D08953
|
Nilotinib
| 5件: 6 6, 8, 34, 51, 86 |
669 |
PPARG
| 11件: PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D00945
D00945
|
Pioglitazone
| 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
670 |
PPARG
| 11件: PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08378
D08378
|
Pioglitazone
| 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
671 |
PPP3CA
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
672 |
PPP3CA
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
673 |
PPP3CB
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
674 |
PPP3CB
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
675 |
PPP3CC
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
676 |
PPP3CC
| 33件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
677 |
PPP3R1
| 32件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
678 |
PPP3R1
| 32件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
679 |
PPP3R2
| 32件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
680 |
PPP3R2
| 32件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
681 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D00291
D00291
|
Desmopressin
| 6件: 6 6, 64, 72, 75, 225, 288 |
682 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D02235
D02235
|
Desmopressin
| 6件: 6 6, 64, 72, 75, 225, 288 |
683 |
CHRNA9
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
684 |
CHRNA9
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
685 |
CHRNA9
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
686 |
PRKAA1
| 20件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D00944
D00944
|
Metformin
| 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
687 |
PRKAA1
| 20件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
688 |
PRKAA2
| 20件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D00944
D00944
|
Metformin
| 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
689 |
PRKAA2
| 20件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
690 |
CACNA2D3
| 7件: MAPK signaling pathway MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
691 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00280
D00280
|
Clonazepam
| 1件: 6 6 |
692 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
693 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
694 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
695 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00696
D00696
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
696 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00697
D00697
|
Flumazenil
| 5件: 6 6, 13, 17, 18, 206 |
697 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
698 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01372
D01372
|
Zopiclone
| 1件: 6 6 |
699 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D02624
D02624
|
Eszopiclone
| 3件: 6 6, 13, 46 |
700 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D05028
D05028
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
701 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| 3件: 6 6, 46, 97 |
702 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
703 |
PRL
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D00780
D00780
|
Bromocriptine
| 2件: 6 6, 74 |
704 |
PRL
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D00987
D00987
|
Cabergoline
| 3件: 6 6, 74, 75 |
705 |
PRL
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D03165
D03165
|
Bromocriptine
| 2件: 6 6, 74 |
706 |
CHRNA10
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
707 |
CHRNA10
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
708 |
CHRNA10
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
709 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00217
D00217
|
Acetaminophen
| 18件: 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 |
710 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00217
D00217
|
Acetaminophen
| 18件: 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 |
711 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00358
D00358
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
712 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
713 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00538
D00538
|
Zonisamide
| 1件: 6 6 |
714 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D00638
D00638
|
Flecainide
| 1件: 6 6 |
715 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D01768
D01768
|
Oxybuprocaine
| 1件: 6 6 |
716 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D02086
D02086
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
717 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D07962
D07962
|
Flecainide
| 1件: 6 6 |
718 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D08127
D08127
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
719 |
SCN1A
| 1件: Dopaminergic synapse Dopaminergic synapse | D08319
D08319
|
Oxybuprocaine
| 1件: 6 6 |
720 |
SCN2A
| 1件: Taste transduction Taste transduction | D00358
D00358
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
721 |
SCN2A
| 1件: Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
722 |
SCN2A
| 1件: Taste transduction Taste transduction | D00538
D00538
|
Zonisamide
| 1件: 6 6 |
723 |
SCN2A
| 1件: Taste transduction Taste transduction | D00638
D00638
|
Flecainide
| 1件: 6 6 |
724 |
SCN2A
| 1件: Taste transduction Taste transduction | D01768
D01768
|
Oxybuprocaine
| 1件: 6 6 |
725 |
SCN2A
| 1件: Taste transduction Taste transduction | D02086
D02086
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
726 |
SCN2A
| 1件: Taste transduction Taste transduction | D07962
D07962
|
Flecainide
| 1件: 6 6 |
727 |
SCN2A
| 1件: Taste transduction Taste transduction | D08127
D08127
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
728 |
SCN2A
| 1件: Taste transduction Taste transduction | D08319
D08319
|
Oxybuprocaine
| 1件: 6 6 |
729 |
SCN3A
| 1件: Taste transduction Taste transduction | D00358
D00358
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
730 |
SCN3A
| 1件: Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
731 |
SCN3A
| 1件: Taste transduction Taste transduction | D00538
D00538
|
Zonisamide
| 1件: 6 6 |
732 |
SCN3A
| 1件: Taste transduction Taste transduction | D00638
D00638
|
Flecainide
| 1件: 6 6 |
733 |
SCN3A
| 1件: Taste transduction Taste transduction | D01768
D01768
|
Oxybuprocaine
| 1件: 6 6 |
734 |
SCN3A
| 1件: Taste transduction Taste transduction | D02086
D02086
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
735 |
SCN3A
| 1件: Taste transduction Taste transduction | D07962
D07962
|
Flecainide
| 1件: 6 6 |
736 |
SCN3A
| 1件: Taste transduction Taste transduction | D08127
D08127
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
737 |
SCN3A
| 1件: Taste transduction Taste transduction | D08319
D08319
|
Oxybuprocaine
| 1件: 6 6 |
738 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D00358
D00358
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
739 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
740 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D00538
D00538
|
Zonisamide
| 1件: 6 6 |
741 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D00638
D00638
|
Flecainide
| 1件: 6 6 |
742 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D01768
D01768
|
Oxybuprocaine
| 1件: 6 6 |
743 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D02086
D02086
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
744 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D07962
D07962
|
Flecainide
| 1件: 6 6 |
745 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D08127
D08127
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
746 |
SCN5A
| 1件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D08319
D08319
|
Oxybuprocaine
| 1件: 6 6 |
747 |
SCN9A
| 1件: Taste transduction Taste transduction | D00358
D00358
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
748 |
SCN9A
| 1件: Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
749 |
SCN9A
| 1件: Taste transduction Taste transduction | D00538
D00538
|
Zonisamide
| 1件: 6 6 |
750 |
SCN9A
| 1件: Taste transduction Taste transduction | D00638
D00638
|
Flecainide
| 1件: 6 6 |
751 |
SCN9A
| 1件: Taste transduction Taste transduction | D01768
D01768
|
Oxybuprocaine
| 1件: 6 6 |
752 |
SCN9A
| 1件: Taste transduction Taste transduction | D02086
D02086
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
753 |
SCN9A
| 1件: Taste transduction Taste transduction | D07962
D07962
|
Flecainide
| 1件: 6 6 |
754 |
SCN9A
| 1件: Taste transduction Taste transduction | D08127
D08127
|
Lidocaine
| 13件: 6 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 |
755 |
SCN9A
| 1件: Taste transduction Taste transduction | D08319
D08319
|
Oxybuprocaine
| 1件: 6 6 |
756 |
SLC6A1
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, GABAergic synapse | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
757 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D00814
D00814
|
Doxepin
| 1件: 6 6 |
758 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D00816
D00816
|
Nortriptyline
| 2件: 6 6, 226 |
759 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D00821
D00821
|
Venlafaxine
| 3件: 6 6, 13, 46 |
760 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D01179
D01179
|
Duloxetine
| 2件: 6 6, 13 |
761 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D01296
D01296
|
Methylphenidate
| 7件: 6 6, 13, 34, 84, 113, 179, 206 |
762 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D02574
D02574
|
Atomoxetine
| 4件: 6 6, 8, 13, 17 |
763 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D04999
D04999
|
Methylphenidate
| 7件: 6 6, 13, 34, 84, 113, 179, 206 |
764 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D07473
D07473
|
Atomoxetine
| 4件: 6 6, 8, 13, 17 |
765 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D07875
D07875
|
Doxepin
| 1件: 6 6 |
766 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D07880
D07880
|
Duloxetine
| 2件: 6 6, 13 |
767 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D08288
D08288
|
Nortriptyline
| 2件: 6 6, 226 |
768 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D08670
D08670
|
Venlafaxine
| 3件: 6 6, 13, 46 |
769 |
SLC6A2
| 1件: Synaptic vesicle cycle Synaptic vesicle cycle | D11688
D11688
|
Ampreloxetine
| 2件: 6 6, 17 |
770 |
SLC6A3
| 7件: Synaptic vesicle cycle Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism | D01296
D01296
|
Methylphenidate
| 7件: 6 6, 13, 34, 84, 113, 179, 206 |
771 |
SLC6A3
| 7件: Synaptic vesicle cycle Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism | D03215
D03215
|
Armodafinil
| 3件: 6 6, 13, 84 |
772 |
SLC6A3
| 7件: Synaptic vesicle cycle Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism | D04999
D04999
|
Methylphenidate
| 7件: 6 6, 13, 34, 84, 113, 179, 206 |
773 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00814
D00814
|
Doxepin
| 1件: 6 6 |
774 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00816
D00816
|
Nortriptyline
| 2件: 6 6, 226 |
775 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00821
D00821
|
Venlafaxine
| 3件: 6 6, 13, 46 |
776 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00822
D00822
|
Citalopram
| 7件: 6 6, 8, 13, 18, 46, 98, 127 |
777 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00825
D00825
|
Sertraline
| 2件: 6 6, 206 |
778 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D01179
D01179
|
Duloxetine
| 2件: 6 6, 13 |
779 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D02260
D02260
|
Paroxetine
| 4件: 6 6, 13, 46, 85 |
780 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D02360
D02360
|
Sertraline
| 2件: 6 6, 206 |
781 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D02362
D02362
|
Paroxetine
| 4件: 6 6, 13, 46, 85 |
782 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D02567
D02567
|
Escitalopram
| 3件: 2 2, 6, 13 |
783 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D05374
D05374
|
Paroxetine
| 4件: 6 6, 13, 46, 85 |
784 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D05375
D05375
|
Paroxetine
| 4件: 6 6, 13, 46, 85 |
785 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07704
D07704
|
Citalopram
| 7件: 6 6, 8, 13, 18, 46, 98, 127 |
786 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07704
D07704
|
Escitalopram
| 3件: 2 2, 6, 13 |
787 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07875
D07875
|
Doxepin
| 1件: 6 6 |
788 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07880
D07880
|
Duloxetine
| 2件: 6 6, 13 |
789 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07913
D07913
|
Escitalopram
| 3件: 2 2, 6, 13 |
790 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D08288
D08288
|
Nortriptyline
| 2件: 6 6, 226 |
791 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D08670
D08670
|
Venlafaxine
| 3件: 6 6, 13, 46 |
792 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D10184
D10184
|
Vortioxetine
| 1件: 6 6 |
793 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D11688
D11688
|
Ampreloxetine
| 2件: 6 6, 17 |
794 |
SLC10A2
| 1件: Bile secretion Bile secretion | D10796
D10796
|
Elobixibat
| 1件: 6 6 |
795 |
SLC12A2
| 3件: Salivary secretion Salivary secretion, Pancreatic secretion, Vibrio cholerae infection | D00247
D00247
|
Bumetanide
| 2件: 6 6, 158 |
796 |
SLC12A2
| 3件: Salivary secretion Salivary secretion, Pancreatic secretion, Vibrio cholerae infection | D00331
D00331
|
Furosemide
| 1件: 6 6 |
797 |
SNAP25
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Insulin secretion | D00783
D00783
|
Botulinum toxin type A
| 13件: 2 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
798 |
SNAP25
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Insulin secretion | D02735
D02735
|
Botulinum toxin type B
| 4件: 2 2, 6, 13, 51 |
799 |
SNCA
| 3件: Alzheimer disease Alzheimer disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases | D11420
D11420
|
Prasinezumab
| 1件: 6 6 |
800 |
SRC
| 42件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, Axon guidance, VEGF signaling pathway, Focal adhesion, Adherens junction, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Bacterial invasion of epithelial cells, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Bladder cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09664
D09664
|
Saracatinib
| 3件: 6 6, 89, 272 |
801 |
SRD5A2
| 3件: Steroid hormone biosynthesis Steroid hormone biosynthesis, Metabolic pathways, Prostate cancer | D00321
D00321
|
Finasteride
| 1件: 6 6 |
802 |
ABCC8
| 3件: ABC transporters ABC transporters, Insulin secretion, Type II diabetes mellitus | D00594
D00594
|
Repaglinide
| 3件: 6 6, 21, 299 |
803 |
UGCG
| 2件: Sphingolipid metabolism Sphingolipid metabolism, Metabolic pathways | D11633
D11633
|
Venglustat
| 3件: 6 6, 19, 67 |
804 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00188
D00188
|
Cholecalciferol
| 25件: 6 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 |
805 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00299
D00299
|
Dihydrotachysterol
| 2件: 6 6, 85 |
806 |
TRPV1
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00250
D00250
|
Capsaicin
| 5件: 2 2, 6, 19, 86, 226 |
807 |
XDH
| 5件: Purine metabolism Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome | D00224
D00224
|
Allopurinol
| 6件: 6 6, 46, 57, 66, 96, 97 |
808 |
XDH
| 5件: Purine metabolism Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome | D01206
D01206
|
Febuxostat
| 3件: 2 2, 6, 13 |
809 |
CA2
| 7件: Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
810 |
CA4
| 3件: Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
811 |
CACNA1C
| 34件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
812 |
CACNA1C
| 34件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
813 |
CACNA1D
| 35件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
814 |
CACNA1D
| 35件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
815 |
CACNA1F
| 27件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
816 |
CACNA1F
| 27件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
817 |
CACNA1S
| 27件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
818 |
CACNA1S
| 27件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
819 |
CACNA2D1
| 7件: MAPK signaling pathway MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
820 |
VKORC1
| 3件: Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors | D00564
D00564
|
Warfarin
| 13件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
821 |
VKORC1
| 3件: Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors | D01280
D01280
|
Warfarin
| 13件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
822 |
VKORC1
| 3件: Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors | D08682
D08682
|
Warfarin
| 13件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
823 |
ALDH5A1
| 3件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
824 |
TAS1R2
| 2件: Taste transduction Taste transduction, Carbohydrate digestion and absorption | D02381
D02381
|
Aspartame
| 5件: 6 6, 13, 67, 86, 230 |
825 |
TAS1R3
| 2件: Taste transduction Taste transduction, Carbohydrate digestion and absorption | D02381
D02381
|
Aspartame
| 5件: 6 6, 13, 67, 86, 230 |
826 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
827 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
828 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D02008
D02008
|
Tadalafil
| 7件: 6 6, 51, 75, 84, 86, 113, 210 |
829 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D02229
D02229
|
Sildenafil
| 17件: 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |
830 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D08514
D08514
|
Sildenafil
| 17件: 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |
831 |
CACNA1I
| 7件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
832 |
CACNA1I
| 7件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D00538
D00538
|
Zonisamide
| 1件: 6 6 |
833 |
CACNA1H
| 7件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
834 |
CACNA1H
| 7件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D00538
D00538
|
Zonisamide
| 1件: 6 6 |
835 |
CACNA1G
| 8件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
836 |
CACNA1G
| 8件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome | D00538
D00538
|
Zonisamide
| 1件: 6 6 |
837 |
CHRNA6
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
838 |
CHRNA6
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction | D05156
D05156
|
Nicotine
| 3件: 6 6, 13, 84 |
839 |
CHRNA6
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction | D05157
D05157
|
Nicotine
| 3件: 6 6, 13, 84 |
840 |
HTR3B
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
841 |
HTR3B
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
842 |
HTR3B
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D00678
D00678
|
Ondansetron
| 4件: 6 6, 97, 107, 231 |
843 |
HTR3B
| 2件: Serotonergic synapse Serotonergic synapse, Taste transduction | D10184
D10184
|
Vortioxetine
| 1件: 6 6 |
844 |
CACNA2D2
| 7件: MAPK signaling pathway MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
845 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D02994
D02994
|
Rituximab
| 49件: 6 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
846 |
CACNA2D4
| 7件: MAPK signaling pathway MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
847 |
SV2A
| 1件: ECM-receptor interaction ECM-receptor interaction | D00709
D00709
|
Levetiracetam
| 3件: 6 6, 13, 307 |
848 |
NR1H4
| 1件: Bile secretion Bile secretion | D00734
D00734
|
Ursodeoxycholic acid
| 14件: 6 6, 8, 20, 46, 67, 84, 93, 94, 95, 96, 97, 234, 296, 299 |